

JC772 U.S. PTO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
REQUEST FOR FILING NATIONAL PATENT APPLICATION  
Under 35 USC 111(a) and Rule 53(b)

J1036 U.S. PRO  
09/840872  
04/25/01

04/25/01

Hon. Commissioner of Patents  
Washington, D.C. 20231

WITH UNSIGNED  
DECLARATION

NONPROVISIONAL  
NON REISSUE  
NON PCT NAT PHASE

PATENT APPLICATION



00909

Sir:

Herewith is the PATENT APPLICATION of  
Inventor(s): Antonio J. Grillo-Lopez

Title INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR  
TREATMENT OF CENTRAL NERVOUS SYSTEM  
LYMPHOMAS

Atty. Dkt.: P 0280609  
M#

Client Ref

including:

Date: April 25, 2001

1. Specification: 75 pages (only spec. and claims) 2.  Specification in non-English language  
3. Declaration  Original  Unsigned Copy  Abstract 1 page(s); 50 numbered claims  
4.  Drawings: sheet(s)  informal;  formal of size:  A4  11"  
5.  See top first page re prior Provisional, National or International application(s). ("X" box only if info is there and do not complete item 6 or 7). (Prior M# 0275477 SN 60/199,365 )

6. This application claims benefit of the following prior US application(s), the contents of which are incorporated into this application by this reference:

No. / filed \_\_\_\_\_  
No. / filed \_\_\_\_\_  
No. / filed \_\_\_\_\_

7.  See the attached Preliminary Amendment, which amends the specification to claim benefit of the above listed US applications

8.  Attached is an assignment and cover sheet. Please return the recorded assignment to the undersigned.  
9.  Assignee (optional): IDEC Pharmaceuticals Corporation

Address San Diego, California

10. FOREIGN priority is claimed under 35 USC 119(a)-(d)/365(b) based on filing in \_\_\_\_\_

11. (country)

Application No.	Filing Date	Application No.	Filing Date
(1)		(2)	
(3)		(4)	
(5)		(6)	
(7)		(8)	
(9)		<input type="checkbox"/> See 3 <sup>rd</sup> page for additional priorities	

12. (No.) Certified copy (copies):  attached;  previously filed (date) \_\_\_\_\_  
in U.S. Application No. / filed on \_\_\_\_\_
13. Small entity status  is not claimed;  is claimed (Pre-filing confirmation required)  
13(a).  Attached: \_\_\_\_\_ (No.) Small Entity Statement(s) (since 9/8/00 small entity statement(s) not essential to make claim).  
13(b).  See NONPUBLICATION REQUEST under Rule 213(a) attached (Pat-258)

14. DOMESTIC/INTERNATIONAL priority is claimed under 35 USC 119(e)/120/365(c) based on the following provisional, nonprovisional and/or PCT international application(s):

Application No.	Filing Date	Application No.	Filing Date
(1) 60/199,365	25 April 2000	(4)	
(2)		(5)	
(3)		(6)	

15.  This application is being filed under Rule 53(b)(2) since an inventor is named in the enclosed Declaration who was not named in the prior application.

16.  Attached:

17.  Preliminary Amendment:

**THE FOLLOWING FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY ABOVE CANCELLED**

				Large/Small Entity		Fee Code
18. Basic Filing Fee				\$710/\$355	\$710	101/201
19. Total Effective Claims	50	minus 20 =	*30	x \$18/\$9 =	+ 540	103/203
20. Independent Claims	5	minus 3 =	*2	x \$80/\$40 =	+ 160	102/202
21. If any proper multiple dependent claim (ignore improper) is present , add (Leave this line blank if this is a reissue application)				*If answer is zero or less, enter "0"		
22. If "non-English" box 2 is X'd, add Rule 17(k) processing fee				+ \$270/\$135	+ 0	104/204
23. If "assignment" box 8 is X'd, add recording fee				+ \$130	+ 0	139
24. If "assignment" box 8 is X'd, add recording fee				+ \$40	+ 0	581
25. <input type="checkbox"/> Attached is a Petition/Fee under Rule No.				+ \$130	+ 0	122
26. <b>TOTAL FEE ENCLOSED =</b>				<b>\$1410</b>	<b>\$1410</b>	

Our Deposit Account No. 03-3975

Our Order No. 037003 | 0280609

C# M#



00909

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficient fee only) now or hereafter relative to this application and the resulting Official document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown above for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal form is filed.

Pillsbury Winthrop LLP  
Intellectual Property Group

By Atty: Robin L. Teskin

Reg. No. 35,030

Sig:

Fax: (202) 822-0944  
Tel: (202) 861-3623

Atty/Sec: RLT/kmh

NOTE: File in duplicate with 2 post card receipts (PAT-103) & attachments